However, in a recent study, miR-27b was found to be down-regulated in HCC and to affect the sensitivities of HCC cells to several therapeutic agents via p53 activation and CYP1B1 suppression [30]. The gene discussed is TP53; the disease is hepatocellular carcinoma.